Table 1.
Control 16 weeks (n = 4) | CCl4 4 weeks (n = 6) | CCl4 8 weeks (n = 6) | CCl4 10 weeks (n = 6) | CCl4 12 weeks (n = 6) | CCl4 16 weeks (n = 6) | |
---|---|---|---|---|---|---|
A: CCl4* | ||||||
CD31 | 55.8 ± 5.6 | 104.3 ± 5.7a,e | 150 ± 14.2b,f | 135 ± 12.0c,g | 151.5 ± 20.5b | 205 ± 10.5d |
Ki67 | 0 | 16.3 ± 5.3d | 25.0 ± 6.9 | 47 ± 4.2a | 31.3 ± 5.3b | 33.7 ± 3.8c |
VEGF | 1 ± 0 | 2 ± 0.2a,e | 2 ± 0.2a,e | 2 ± 0.4b | 2 ± 0.5c | 3 ± 0d |
Sham-operated 6 weeks (n = 4) | CBDL 1 week (n = 6) | CBDL 3 weeks (n = 6) | CBDL 6 weeks (n = 6) | |
---|---|---|---|---|
B: Common bile duct ligation† | ||||
CD31 | 55.8 ± 5.6 | 80.8 ± 5.9a,b | 181.8 ± 23.1a | 147.8 ± 35.0a |
Ki67 | 0 | 2 ± 0 | 33.7 ± 4.8a, b | 30.0 ± 10.0 |
VEGF | 1 ± 0 | 2 ± 0.2a,b | 3 ± 0.2a | 3 ± 0a |
CD31: aP = 0.05 vs. control, bP = 0.006 vs. control, cP = 0.011 vs. control, dP = 0.004 vs. control, eP = 0.004 vs. 16 weeks CCl4, fP = 0.028 vs. 16 weeks CCl4, gP = 0.010 vs. 16 weeks CCl4
Ki67: aP = 0.007 vs. control, bP = 0.009 vs. control, cP = 0.01 vs. control, dP = 0.01 vs. 10 weeks
VEGF: aP = 0.003 vs. control, bP = 0.004 vs. control, cP = 0.016 vs. control, dP = 0.001 vs. control, eP = 0.004 vs. 16 weeks CCl4.
CD31: aP < 0.01 vs. sham-operated, bP= 0.001 vs. CBDL 3 and 6 weeks
Ki67: aP= 0.02 vs. sham-operated, bP= 0.02 vs. CBDL 1 week
VEGF: aP= 0.001 vs. sham-operated, bP= 0.002 vs. CBDL 3 and 6 weeks.